Tevogen Bio (NASDAQ:TVGNW – Get Free Report) is expected to announce its resultson Wednesday, June 3rd. Analysts expect the company to announce earnings of ($2.64) per share for the quarter.
Tevogen Bio Trading Up 0.2%
Shares of NASDAQ:TVGNW opened at $0.04 on Wednesday. The business’s fifty day moving average price is $0.03 and its two-hundred day moving average price is $0.04. Tevogen Bio has a fifty-two week low of $0.03 and a fifty-two week high of $0.08.
Tevogen Bio Company Profile
Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing.
The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors.
Read More
- Five stocks we like better than Tevogen Bio
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
